OVID Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

62.60K

-17.63%

-0.108

-16.92%

33.33K

-74.36%

-0.104

-25.89%

33.33K

-99.47%

-0.105

+75%

Estimates Revision

The market is revising Downward the revenue expectations for Ovid Therapeutics Inc. (OVID) for FY2025, with the revenue forecasts being adjusted by -0.96% over the past three months. During the same period, the stock price has changed by -0.57%.

Revenue Estimates for FY2025

Revise Downward

-0.96%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.7%

In Past 3 Month

Stock Price

Go Down

-0.57%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is 4.58 USD with a low forecast of 1.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

1.50

Averages

4.58

High

7.00

Current: 0.000

Low

1.50

Averages

4.58

High

7.00

LifeSci Capital

Outperform

initiated

2025-12-22

Reason

LifeSci Capital

Price Target

2025-12-22

initiated

Outperform

Reason

LifeSci Capital initiated coverage of Ovid Therapeutics with an Outperform rating and $4 price target.

Roth Capital

Boobalan Pachaiyappan

Buy

initiated

2025-12-11

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

2025-12-11

initiated

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Ovid Therapeutics with a Buy rating and $3 price target. The firm views Ovid's OV329 as a "differentiated" oral agent targeting a sub-population of the epilepsy therapy market. It believes this market is in a "dire need of new medicines."

H.C. Wainwright

Buy

maintain

2025-11-24

Reason

H.C. Wainwright

Price Target

2025-11-24

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Ovid Therapeutics to $2 from $1.50 and keeps a Buy rating on the shares. OV329's initial clinical data show robust safety and position the compound favorably for proof-of-concept clinical development, the analyst tells investors in a research note.

Leerink

initiated

2025-11-17

Reason

Leerink

Price Target

2025-11-17

initiated

Reason

Leerink initiated coverage of Ovid Therapeutics with an Outperform rating and $5 price target.

Leerink

Marc Goodman

Outperform

initiated

2025-11-17

Reason

Leerink

Marc Goodman

Price Target

2025-11-17

initiated

Outperform

Reason

As previously reported, Leerink analyst Marc Goodman initiated coverage of Ovid Therapeutics with an Outperform rating and $5 price target. The firm notes OV329 is a second-gen GABA-AT inhibitor with greater potency and potentially improved safety, including the lack of retinal toxicity compared with the first-gen GABA-AT inhibitor. Leerink likes the epilepsy market; the FDA wants to approve new drugs, payer pushback is relatively low since patients are refractive to many AEDs, polypharmacy is the norm, so this is not a zero-sum game, and importantly physicians like to try new therapies. The firm believe the KCC2 portfolio represents an interesting opportunity targeting a novel mechanism with strong biological validation, as genetic and preclinical evidence links KCC2 dysregulation to developmental and neuropsychiatric disorders.

Lucid Capital

NULL -> Buy

initiated

$5.50

2025-08-13

Reason

Lucid Capital

Price Target

$5.50

2025-08-13

initiated

NULL -> Buy

Reason

Lucid Capital initiated coverage of Ovid Therapeutics with a Buy rating and $5.50 price target. The firm says Ovid is developing drugs to treat epilepsies and seizure-related neurological disorders. The company's OV329 could capture a significant market share in drug-resistant epilepsy, reaching over $1B in sales in the U.S., five years after launch, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Ovid Therapeutics Inc (OVID.O) is -4.15, compared to its 5-year average forward P/E of -3.28. For a more detailed relative valuation and DCF analysis to assess Ovid Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.28

Current PE

-4.15

Overvalued PE

-1.23

Undervalued PE

-5.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.36

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

6.39

Undervalued EV/EBITDA

-5.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

332.35

Current PS

1409.13

Overvalued PS

890.97

Undervalued PS

-226.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 668.25% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OVID News & Events

Events Timeline

No data

News

9.0

2025-12-18Newsfilter

Ovid Therapeutics Advances KCC2 Oral Activator OV4071 Clinical Trial Plans

5.0

2025-12-02Globenewswire

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development

5.0

2025-12-02Newsfilter

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development

People Also Watch

Frequently Asked Questions

What is Ovid Therapeutics Inc (OVID) stock price today?

The current price of OVID is 1.73 USD — it has increased 0 % in the last trading day.

What is Ovid Therapeutics Inc (OVID)'s business?

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

What is the price predicton of OVID Stock?

What is Ovid Therapeutics Inc (OVID)'s revenue for the last quarter?

Ovid Therapeutics Inc revenue for the last quarter amounts to 132.00K USD, decreased -23.70 % YoY.

What is Ovid Therapeutics Inc (OVID)'s earnings per share (EPS) for the last quarter?

Ovid Therapeutics Inc. EPS for the last quarter amounts to -0.17 USD, decreased -15.00 % YoY.

What changes have occurred in the market's expectations for Ovid Therapeutics Inc (OVID)'s fundamentals?

How many employees does Ovid Therapeutics Inc (OVID). have?

Ovid Therapeutics Inc (OVID) has 23 emplpoyees as of January 09 2026.

What is Ovid Therapeutics Inc (OVID) market cap?

Today OVID has the market capitalization of 225.22M USD.